€7.05
4.50% yesterday
Xetra, Jul 31, 05:36 pm CET
ISIN
DE0005664809
Symbol
EVT
Index

Evotec Stock price

€7.05
-0.16 2.19% 1M
-1.60 18.54% 6M
-1.15 14.02% YTD
-1.67 19.20% 1Y
-19.15 73.11% 3Y
-15.37 68.57% 5Y
+3.60 104.71% 10Y
+4.17 144.65% 20Y
Xetra, Closing price Thu, Jul 31 2025
-0.33 4.50%

Key metrics

Basic
Market capitalization
€1.3b
Enterprise Value
€1.4b
Net debt
€100.0m
Cash
€378.7m
Shares outstanding
177.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1.7 | 1.6
EV/Sales
1.8 | 1.8
EV/FCF
negative
P/B
1.4
Financial Health
Equity Ratio
49.8%
Return on Equity
-20.6%
ROCE
-5.0%
ROIC
-6.6%
Debt/Equity
0.5
Financials (TTM | estimate)
Revenue
€788.2m | €806.0m
EBITDA
- | €53.1m
EBIT
€-79.5m | €-65.5m
Net Income
€-207.0m | €-51.2m
Free Cash Flow
€-80.3m
Growth (TTM | estimate)
Revenue
1.5% | 1.1%
EBITDA
- | 134.1%
EBIT
-3.8% | 17.0%
Net Income
-128.2% | 73.9%
Free Cash Flow
69.9%
Margin (TTM | estimate)
Gross
13.6%
EBITDA
- | 6.6%
EBIT
-10.1%
Net
-26.3% | -6.4%
Free Cash Flow
-10.2%
More
EPS
€-1.2
FCF per Share
€-0.5
Short interest
-
Employees
5k
Rev per Employee
€170.0k
Show more

Is Evotec a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,020 stocks worldwide.

Evotec Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Evotec forecast:

8x Buy
67%
4x Hold
33%

Analyst Opinions

12 Analysts have issued a Evotec forecast:

Buy
67%
Hold
33%

Financial data from Evotec

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
788 788
1% 1%
100%
- Direct Costs 681 681
10% 10%
86%
107 107
31% 31%
14%
- Selling and Administrative Expenses 190 190
10% 10%
24%
- Research and Development Expense 45 45
32% 32%
6%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -79 -79
4% 4%
-10%
Net Profit -207 -207
128% 128%
-26%

In millions EUR.

Don't miss a Thing! We will send you all news about Evotec directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Evotec Stock News

AD HOC NEWS
2 days ago
Der kriselnde Hamburger Wirkstoffforscher und -entwickler Evotec DE0005664809 wird sich im Zuge seines Umbaus voraussichtlich auch von seinen Aktivitäten in Toulouse trennen.
More Evotec News

Company Profile

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmes on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

Head office Germany
CEO Christian Wojczewski
Employees 4,740
Founded 1993
Website www.evotec.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today